Oura's $625 million Counsel Health deal could boost its IPO appeal and help prove wearables’ clinical value.
Oura's deal with Ulta mirrors the recent Whoop-Ulta tie-up. Beauty retail offers a new arena for wearables to compete for shoppers beyond fitness enthusiasts.
Pharma marketers should prioritize treatment continuity by addressing practical barriers to medication access.
A lighter MLB postseason may explain part of the drop as brands weigh linear costs against CTV reach.
With access to the popular treatments losing its power as a differentiator, telehealth brands must compete on care, support, and experience.
Healthcare marketers and providers must be transparent about how and when AI is used in patient care and seek consent where appropriate.
Strong Q3 sales help offset injectable weakness and give Novo an early edge in oral obesity treatments.
Faster content production may deliver limited gains if medical and legal reviews can't keep pace.
CVS' breakup tests standalone pharmacy economics while potentially redirecting regulatory scrutiny toward integrated rivals like UnitedHealth.
Whoop’s partnership with Ulta opens a new sales channel as consumers combine health, wellness, and beauty spending.
Linear is key to reaching broad audiences, while CTV adds more precise targeting.
Questions about symptoms, sleep, and medications create an opening for more personalized healthcare guidance.
Marketers have spent years finding ways to make consumers stop scrolling, watch longer, or notice a message. But those measures offer little indication of whether someone is actually interested in what the advertiser has to say. Advertisers need to look beyond attention and consider receptivity, or whether consumers are open to receiving a message in the first place, according to executives from PulsePoint, Bristol Myers Squibb (BMS), Gilead, and PHM at an Advertising Week New York panel.
As shoppers buy more protein-rich desserts, breads, and snacks, brands must prove health benefits beyond protein content.
Users value AI's convenience and detailed responses, yet harmful guidance and lawsuits could derail broader consumer health AI rollouts.
Its need for replacement revenues could get costlier as more drugmakers seek acquisitions.
Newly required disclosures of opaque PBM fees could prompt more employers to explore smaller PBMs and direct-to-employer drug deals.
Just 14% fully trust institutions, leaving room for women-focused services to address unmet needs.
Telehealth brands can tap rising consumer demand for wellness peptides, though weak clinical evidence heightens patient risks.
Strong demand offsets price cuts, creating opportunities for marketers to focus on patient retention.